Collegium Pharmaceutical/$COLL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Ticker
$COLL
Sector
Primary listing
Employees
423
Headquarters
Website
COLL Metrics
BasicAdvanced
$1.1B
20.45
$1.73
0.68
-
Price and volume
Market cap
$1.1B
Beta
0.68
52-week high
$50.79
52-week low
$24.47
Average daily volume
631K
Financial strength
Current ratio
1.571
Quick ratio
1.359
Long term debt to equity
300.33
Total debt to equity
310.409
Interest coverage (TTM)
2.35%
Profitability
EBITDA (TTM)
419.164
Gross margin (TTM)
88.47%
Net profit margin (TTM)
8.05%
Operating margin (TTM)
24.74%
Effective tax rate (TTM)
32.12%
Revenue per employee (TTM)
$1,850,000
Management effectiveness
Return on assets (TTM)
7.27%
Return on equity (TTM)
23.70%
Valuation
Price to earnings (TTM)
20.445
Price to revenue (TTM)
1.441
Price to book
3.73
Price to tangible book (TTM)
-2.19
Price to free cash flow (TTM)
3.433
Free cash flow yield (TTM)
29.13%
Free cash flow per share (TTM)
10.332
Growth
Revenue change (TTM)
23.62%
Earnings per share change (TTM)
-6.56%
3-year revenue growth (CAGR)
18.94%
3-year earnings per share growth (CAGR)
32.84%
10-year earnings per share growth (CAGR)
1.61%
What the Analysts think about COLL
Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.
COLL Financial Performance
Revenues and expenses
COLL Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Collegium Pharmaceutical stock?
Collegium Pharmaceutical (COLL) has a market cap of $1.1B as of April 12, 2026.
What is the P/E ratio for Collegium Pharmaceutical stock?
The price to earnings (P/E) ratio for Collegium Pharmaceutical (COLL) stock is 20.45 as of April 12, 2026.
Does Collegium Pharmaceutical stock pay dividends?
No, Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders as of April 12, 2026.
When is the next Collegium Pharmaceutical dividend payment date?
Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders.
What is the beta indicator for Collegium Pharmaceutical?
Collegium Pharmaceutical (COLL) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.